TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05949957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LvL UP App
Description: LvL UP App: A Smartphone-based conversational agent-delivered holistic lifestyle intervention. The intervention group will receive several digital coaching sessions focus on 3 pillars: diet, physical activity, and mental well-being to promote health literacy and promote healthy lifestyles. The app includes practical exercises per pillar (e.g., journaling, slow-breathing exercises, lifehacks).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAPPY App
Description: HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAPPY App
Description: HAPPY App: Each subject will use the HAPPY App that aims to:(1) deliver health promotion information (guided by Singapore Health Promotion Board's resources), and (2) display health data collected (e.g., body mass index, blood pressure, OGTT results) that help them monitor own health and prevent T2D.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oura Ring And Oura App
Description: Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oura Ring And Oura App
Description: Oura ring and Oura App: Each subject will receive an Oura ring, i.e., an activity-tracking wearable that collects lifestyle data (physical activity, sleep and heart rate (as a proxy for stress) that will be synced with Oura App
Study: NCT05745844

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: activity sessions
Description: 77 activity sessions ; muscle strengthening, testing or unloading

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity sessions
Description: 77 activity sessions ; muscle strengthening, testing or unloading
Study: NCT06260878

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ringer's lactate
Description: Intravenous Ringer's lactate
Study: NCT05711095

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 20 grams of protein dissolved in 500 mL water from a non-transparent shaker
Study: NCT06639269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fertility health education program
Description: The intervention group will be implemented with a fertility health education program for which a literature information document will be created. In the training; booklets and brochures will be prepared. The control unit will include information on programming and data collection forms to be used. Those selected from the intervention group will be divided into groups of 10-15 people. The training program will consist of 3 sessions. Training sessions will be planned on days and hours that are convenient for the researcher, classrooms and students. For students who cannot attend group training, make-up training will be provided within a week. In this study, the time between sessions will be planned as 1 week. The sessions in this study will be planned to be in groups of 10-15 people and will last 50 minutes.
Study: NCT06242964

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management - Social Needs (PRISM-SN)
Description: The Promoting Resilience in Stress Management - Social Needs (PRISM-SN) intervention is a brief, skill-based psychosocial program. Five core sessions are delivered one-on-one, 1-2 weeks apart, in-person or via videoconference. Sessions teach evidence-based behavioral skills for managing stress, setting goals, reframing negative thoughts, meaning-making, and connecting with others. Each session lasts \<60 minutes and is supported by paper-and-pencil or mobile app-based worksheet(s) for learning and practice. A final review session may be completed individually or with a family member, caregiver, or significant other.
Study: NCT06641531

Intervention type: OTHER
Intervention: Screening pap smear test
Description: The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain

Intervention type: OTHER
Intervention: Screening pap smear test
Description: The patient put in dorsal lithotomy position and place the feet in stirrups or on foot rests . then, the physician will insert a cusco speculum into the vagina to hold vaginal wall open . The specimens will be collected as follows; firstly, the speculum will be inserted without lubricant. Any mucous, discharge or blood will be removed with dry cotton. A wooden spatula will be used for sampling ectocervix which will be rotated 360 degrees. For sampling endocervix, A brush or a swab will be rotated only 90 degrees as the circumferential bristles will be in contact with the entire surface the moment the brush is inserted.~The samples will be applied to the slides which will be encoded and immediately fixed in 95% ethanol and the samples will be transferred to pathology department to be stained by the standard Papanicolaou stain
Study: NCT04725110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Instilled T3
Description: The first dose of T3 (50 micrograms in 10 mls volume BID) will be instilled by an investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. T3 doses will be given in 50 mcg doses twice daily for 4 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Therapy
Description: A placebo therapy will be instilled into the lungs by the investigator or under their direct supervision within 48 hours of obtaining consent after verifying that the patient is not too unstable to treat at that time. Doses will be given twice daily for 4 days.
Study: NCT06197581

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Description: Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Description: Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Description: Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
Study: NCT06467435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamuvudine-9
Description: 96 mg tablets taken twice a day for 4 weeks
Study: NCT06197581

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Description: Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.

Intervention type: RADIATION
Group type: OTHER
Intervention: Chest wall / breast radiation with or without lymph node region radiation.(For all of the enrolled patients)
Description: Patients will receive chest wall / breast radiation with or without lymph node region radiation and novel drugs(for specific population according to guidelines) concurrently.
Study: NCT06641661

Intervention type: DRUG
Intervention: Hybutimibe 10mg QD
Description: Hybutimibe was added to the conventional treatment
Study: NCT06563739

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent low energy shock wave
Description: Receive divergent low energy shock wave once a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent low energy shock wave
Description: Receive divergent low energy shock wave twice a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent medium and low energy shock wave
Description: Receive divergent medium and low energy shock wave once a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent medium and low energy shock wave
Description: Receive divergent medium and low energy shock wave twice a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focused low energy shock wave
Description: Receive focused low energy shock wave once a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent medium energy shock wave
Description: Receive divergent medium energy shock wave once a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Divergent medium energy shock wave
Description: Receive divergent medium energy shock wave twice a week

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-exposed group
Description: Traditional rehabilitation assessment and training guidance
Study: NCT06564428

Intervention type: GENETIC
Intervention: Suspective gene mutations and family history
Description: To observe if the patients with suspective gene mutations or family history take higher risk of suffering from ovarian cancer.
Study: NCT06639126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild thyme extract
Description: All patients will be randomized (1:1) to receive the active thyme extract (600 mg/capsule/day or 600 mg/capsule/day of microcrystalline cellulose) in the form of capsules, administered orally and daily for 2 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg/day microcrystalline cellulose
Study: NCT06294990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone gel
Description: Two years treatment with testosterone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two years treatment with placebo
Study: NCT06639399

Intervention type: OTHER
Intervention: Acupuncture
Description: Patients received acupuncture treatment at the lumbosacral region, all acupoints belong to the bladder meridian, including Shenshu (BL23), Pangguangshu (BL28), Ciliao (BL32), Huiyang (BL35), and Zhibian (BL54) selected bilaterally. Electroacupuncture (EA) was applied to the BL32 and BL54 acupoints at a frequency of 2/100Hz. Each treatment lasting for 30 minutes. Patients received five acupuncture treatments per week for two consecutive weeks

Intervention type: OTHER
Intervention: Acupuncture
Description: Patients received acupuncture treatment using a comprehensive acupoint combination scheme. In addition to the acupoints used in Group A, the following acupoints were added: Qihai (RN6), Guanyuan (RN4), Zhongji (RN3), Shuidao (ST28), Yinglingquan (S9), and Sanyinjiao (SP6). The acupuncture and EA procedure for the lumbosacral acupoints was the same as in Group A. After 30 minutes of treatment, abdominal and lower limb acupoints were selected for an additional 30 minutes treatment.Each treatment lasting for 60 minutes.Patients received five acupuncture treatments per week for two consecutive weeks
Study: NCT06637137

Intervention type: DRUG
Intervention: Iron
Description: Patients who present a state of hypoferritinemia or a state of reduced transferrin saturation will undergo administration of i.v iron at least 2 weeks before scheduled cardiac surgery, plus acid folic and B vitamin co-administration.
Study: NCT06565286

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inner preputial graft versus transverse preputial island flap in two-stage repair of proximal penile hypospadias
Description: compare outcomes of inner preputial graft versus transverse preputial island flap when used to substitute the urethral plate in two-stage repair of primary proximal penile hypospadias .
Study: NCT06467435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kamuvudine-9
Description: 96 mg tablets taken once
Study: NCT06022393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Reappraisal
Description: Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to cognitively reappraise fear or anger inducing situations and are encouraged to implement this strategy into their daily lifes.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Reflection
Description: Patients complete 14 tasks on an app in a time span of 4 weeks in which they are asked to reflect on certain topics of their day.
Study: NCT05964699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive periodontal therapy with use of Emdogain
Description: Scaling of root with assisted use of the Videoscope and regrowth of attachment by the use of Emdogain.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Minimally invasive periodontal therapy without the use of Emdogain
Description: Scaling of root with assisted use of the Videoscope.
Study: NCT06557863

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeCareToFeedDysphagia web tool
Description: The web tool uses written and video content, care-partner testimonials, frequently asked questions, and resource links to provide accurate information (e.g., dysphagia diets), set realistic expectations, identify/support feeding goals (quality of life considerations), acknowledge/support care-partner feelings, and provide competencies/skills for oropharyngeal dysphagia (OD) management.
Study: NCT04998630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Treatment Location: Painful Area Treatment intensity: 2000 pulses, low energy (0.08\~0.28 mJ/m2) the degree to which the subject can tolerate
Study: NCT06529627

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection
Description: pituitary downregulation with GnRH agonist - ovarian stimulation with exogenous gonadotropin - hCG adminstration as trigger of oocyte maturation Oocyte retriveal via transvaginal ultrasound guided aspiration embryo transfer progesterone as luteal phase support
Study: NCT05603676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent hypoxia-hyperoxia conditioning
Description: The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia-hyperoxia conditioning
Description: The IHHC protocol consist of 6 bouts of 6 min breathing hypoxia (FiO2 = 11.5%) following by 3 min breathing hyperoxia (FiO2 = 31.5%) (Figure 2). The total duration of a session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with hypo and hyperoxic gas mixture. Participants will be instructed to relax and breath normally throughout the session.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: Placebo intervention will be like the IHHC protocol but with mixing chambers full of ambient air. The total duration of a placebo session is 54 minutes. Participant will undergo 3 session a week for 6 weeks. During the session, participant will be comfortably seated on an armchair and equipped with a mask and a non-rebreathing valve rely to a motorized valve that blindly change the gas input from two different mixing chambers with ambient air. Participants will be instructed to relax and breath normally throughout the session.
Study: NCT06052553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TopSpin360
Description: Helmet training device used to train head to stay stable during jarring impacts through dynamic and multi-planar neck strengthening.
Study: NCT06275867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free high-quality care
Description: Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free high-quality care
Description: Participants are able to take their child to receive free consultations and treatment in a network of contracted private healthcare providers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Close distance
Description: The network of contracted providers is located close to where participants live.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Far distance
Description: The network of contracted providers is located far to where participants live.
Study: NCT05516875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010
Description: JM-010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JM-010
Description: JM-010
Study: NCT05200481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 MG
Description: Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.

Intervention type: DRUG
Group type: OTHER
Intervention: Brigatinib 180 MG
Description: Patients will receive brigatinib orally at a dose of 90 mg QD for a 7 days lead-in period followed by 180 mg QD continuously, with or without food, in 28-day cycles until progression. Dose reductions are possible.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Patients will receive pemetrexed 500 mg/m² followed by carboplatin to target AUC of 5 mg/mL/min both on Day 1 as IV infusion every 3 weeks for 4 infusions. The first infusion of carboplatin and pemetrexed will be administrated at day 8 of brigatinib treatment, at time of dose escalation from 90 mg QD to 180mg QD continuously.
Study: NCT06040827

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.

Intervention type: DEVICE
Intervention: Total Knee Arthroplasty
Description: The nature, severity, and frequency of safety risks (Adverse Events) in subjects with the Canary canturioTM te will be compared to those subjects with the legally marketed Zimmer Persona® Personalized Knee System with 14 mm x +30 mm stem extension within 5 years post-TKA.
Study: NCT06099405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-speed, Cognitive Challenge Yoga
Description: Participants in this group will receive high-speed yoga with cuing 3 times per week for 24 consecutive weeks for a total of 72 training sessions of 1 hour duration. Subjects will move as quickly as possible from one pose to another.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional yoga
Description: Participants will perform controlled speed Hatha yoga 3 times per week for 24 weeks for a total of 72 sessions of 1 hour duration.
Study: NCT05620940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol Injectable Product
Description: Naltrexone Long-Acting Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3004
Description: Naltrexone Long-Acting Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL3004
Description: Naltrexone Long-Acting Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVL4002
Description: Naltrexone Long-Acting Injection
Study: NCT05847153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MASC
Description: The intervention arm will be comprised of:~1. Six Virtual Group Sessions. The sessions will teach mindfulness, self-compassion and behavioral management skills.~2. At Home Practice. After each group session, participants will have the opportunity to integrate the practices learned into their everyday life.
Study: NCT06134401

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: nebulised

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: saline
Description: nebulised